PanTera Secures €93M to Tackle Alpha-Emitter Isotope Shortage Amid Growing Demand

Funding:
PanTera has secured €93 million to address the shortage of alpha-emitters, which are crucial for certain cancer treatments.

Alpha-Emitters:
Alpha-emitters like Actinium-225 and Radium-224 are used in targeted alpha therapy (TAT) for cancer treatment due to their high energy and short range, which minimizes damage to healthy tissues.

Growing Interest:
There is a growing interest in alpha-emitters for medical applications, particularly in treating solid tumors where traditional radiation therapies may be less effective.

Isotope Production:
The production of alpha-emitters is limited, with only a few sources worldwide, such as the Institute for Transuranium Elements in Karlsruhe, Germany, and Oak Ridge National Laboratory in the USA.

Challenges:
The use of alpha-emitters in medical treatments faces challenges such as low availability, complex chemical properties, and the need for strict safety measures to prevent contamination.